Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide scheduling strategies in newly diagnosed glioblastoma
ACTRN12620000048987Phase 3Completed
- Sponsor
- NHMRC Clinical Trials Centre
- Start
- Sep 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of temozolomide in glioblastoma (GBM), sponsored by NHMRC Clinical Trials Centre. Started Sep 2020; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12620000048987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000048987.